Comparison of pentamidine isethionate and trimethoprim-sulfamethoxazole in the treatment of Pneumocystis carinii pneumonia.
about
Treatment of infection due to Pneumocystis cariniiActivities of antifolate, antiviral, and other drugs in an immunosuppressed rat model of Pneumocystis carinii pneumoniaFurazolidone and nitrofurantoin in the treatment of experimental Pneumocystis carinii pneumoniaFractal Geometry-Based Decrease in Trimethoprim-Sulfamethoxazole Concentrations in Overweight and Obese People.Pneumocystis carinii pneumonia.Cotrimoxazole - optimal dosing in the critically ill.Pneumocystis carinii, Toxoplasma gondii, Cytomegalovirus and the compromised hostIsolation and expression of the Pneumocystis carinii dihydrofolate reductase gene.Pneumonia in the acquired immune deficiency syndrome.Serum peak sulfamethoxazole concentrations demonstrate difficulty in achieving a target range: a retrospective cohort study.Intravenous pentamidine is effective as second line Pneumocystis pneumonia prophylaxis in pediatric oncology patients.Outbreaks of Pneumocystis carinii pneumonia in colonies of immunodeficient mice.Recent advances in the diagnosis, treatment, and prevention of Pneumocystis carinii pneumoniaInhibitors of folic acid synthesis in the treatment of experimental Pneumocystis carinii pneumoniaManagement of Pneumocystis Jirovecii pneumonia in HIV infected patients: current options, challenges and future directions.Efficacy of diaminodiphenylsulfone and other drugs in murine Pneumocystis carinii pneumonitis.Multiple-dose pharmacokinetics of 12 milligrams of trimethoprim and 60 milligrams of sulfamethoxazole per kilogram of body weight per day in healthy volunteers.Alveolar response to experimental Pneumocystis carinii pneumonia in the rat.Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients.The biology of Pneumocystis carinii.The ecology of pneumocystis: perspectives, personal recollections, and future research opportunitiesPulmonary fungal infection with yeasts and pneumocystis in patients with hematological malignancy.AIDS and the lung. 7. Treatment of lung disease in patients with the acquired immune deficiency syndrome.Limited effect of trimethoprim-sulfamethoxazole prophylaxis on Pneumocystis cariniiPharmacokinetics and adverse effects of 20-mg/kg/day trimethoprim and 100-mg/kg/day sulfamethoxazole in healthy adult subjectsHematologic and oncologic complications in the critically ill child.Historical perspectives on Pneumocystis carinii.Animal models for Pneumocystis carinii pneumonia.Clinical studies of Pneumocystis carinii and relationships to AIDS.Pulmonary infections in immunocompromised children.Prevention of infection due to Pneumocystis carinii.Pharmacokinetics of trimethoprim-sulfamethoxazole in critically ill and non-critically ill AIDS patients.Zidovudine, trimethoprim, and dapsone pharmacokinetic interactions in patients with human immunodeficiency virus infection.Dapsone treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome.Treatment of Pneumocystis jirovecii pneumonia in HIV-infected patients: a review.Therapeutic progress. IV: Treatment and prophylaxis of Pneumocystis carinii infection.Hypersensitivity anaphylactoid reaction to pefloxacin in a patient with AIDS.Intermittent chemoprophylaxis for Pneumocystis carinii pneumonia.Trimethoprim/sulfamethoxazole-induced tremor in a patient with AIDS.Prophylaxis of Pneumocystis carinii pneumonia with atovaquone in children with leukemia.
P2860
Q24519016-342BA6D9-41B8-4991-8597-8E5DCB8DFAA9Q28316960-EF5BEF52-C35C-47DA-B880-C76F3FC43FFFQ28335355-A95CF72B-207A-4416-9516-AC2C2D3291D0Q30395441-36AC47E0-FD1B-4094-AD80-02C9872CC8E4Q33603768-7645E554-7453-4178-BCB8-8E332FB41199Q33652427-8DE714A9-3D98-4B89-9972-388090F633C6Q34052214-8A121037-594F-4F6D-BCB4-307310A2AB8DQ34317942-6AC54731-C4C0-4C86-9B6A-EC24B65A81FAQ34484229-1B7924F4-90C7-4C80-9C1C-68E6F8C21C79Q34498991-6F4EB754-ABB9-4345-B9AF-9976DCA3E073Q34754990-365308A7-BB3E-4526-B9E7-4D98FE4EE7B4Q35088499-A95B7200-6F2F-4828-B21B-AD2CD868B3ECQ35251483-B062BC6B-EDF0-4E30-8D33-A6AAA96857DAQ35289230-5F608ED3-7637-463A-BB52-64D4CA01CC02Q35557252-D0E49BB5-91F3-4D3A-A0DE-2B02C0198530Q35639856-05B31587-EED2-48C6-9982-CFA25E67EE2CQ35810094-E7DB9006-5038-4B2C-BEA8-470237B90478Q35863715-80AF1E19-6C80-402B-AC93-F17EF7F3365BQ35920640-6C395159-E516-4F0A-A528-098375890968Q35949839-4B14CB85-BC7E-49D5-AF34-F2DDE1FD09A7Q36082802-A8FC2B61-60BC-4A5E-9517-70F2D1AFB9FCQ36194915-1ED9E38A-45B4-43E0-AFAD-D242A7567CD9Q36217668-384CDABF-C6C5-4D51-BD52-7060D2B414E2Q36483707-DF7E2A76-C8F9-431A-8EAA-82A85555C9E0Q36754937-863ACBFA-C6FF-4156-89ED-4A5E9833A75EQ36988724-74F51403-11AA-47C7-AC34-D80CAEAD61E2Q38620122-6271FB4C-C4D0-4C15-875F-A933F94BE08FQ38620125-1F04AA54-545B-42B2-B224-0899E54EAD6CQ38620142-2603DC2A-2737-4298-82CC-67B7D9932CEEQ38785599-E1D69E18-72C0-4A67-B50E-150C799A18BCQ39558319-3A39B34D-0E9B-4D9E-B09E-19550801A6E5Q39778838-6FF3BDAA-42D1-4C5C-AB88-432E5C923B0FQ39782074-85624B69-48C9-4570-8532-DF387C3EFEFAQ39818520-78438393-FD9D-4AF4-9D34-9D7DB01DBCEBQ40092648-C426180E-2933-4FCF-AC58-9BAAB6A7992EQ40434099-747A2E9D-79FA-49CE-899C-CA2CA4889508Q40667645-990478ED-B9A6-4D19-AC2B-8C208983424CQ42136911-12D142BA-573C-446C-9648-8F79DFEDA973Q42544613-739CC23F-ADF9-4D1C-95DB-6A00FCA9846BQ43861698-A6BF9786-D0FD-4E50-97BE-AA47660560AE
P2860
Comparison of pentamidine isethionate and trimethoprim-sulfamethoxazole in the treatment of Pneumocystis carinii pneumonia.
description
1978 nî lūn-bûn
@nan
1978年の論文
@ja
1978年論文
@yue
1978年論文
@zh-hant
1978年論文
@zh-hk
1978年論文
@zh-mo
1978年論文
@zh-tw
1978年论文
@wuu
1978年论文
@zh
1978年论文
@zh-cn
name
Comparison of pentamidine iset ...... neumocystis carinii pneumonia.
@en
type
label
Comparison of pentamidine iset ...... neumocystis carinii pneumonia.
@en
prefLabel
Comparison of pentamidine iset ...... neumocystis carinii pneumonia.
@en
P2093
P1476
Comparison of pentamidine iset ...... neumocystis carinii pneumonia.
@en
P2093
P304
P356
10.1016/S0022-3476(78)80028-6
P407
P577
1978-02-01T00:00:00Z